MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
stock under equity...
$1,793K
Net cash provided by
financing activities
$1,793K
Net (decrease)
increase in cash and cash...
-$75,363K
Canceled cashflow
$1,793K
Contract liabilities
$195,715K
Share-based compensation
expense
$37,108K
Accrued expenses and
other current...
$12,654K
Accounts payable
$4,499K
Other long-term
liabilities
$1,043K
Depreciation expense
$1,032K
Non-cash interest
expense
$515K
Maturities of short-term
investments
$755,128K
Net cash (used in)
provided by operating...
-$64,058K
Net cash (used in)
provided by investing...
-$13,098K
Canceled cashflow
$252,566K
Canceled cashflow
$755,128K
Total revenue
$67,482K
Interest and other
income, net
$26,774K
Net loss
-$278,666K
Purchases of short-term
investments
$761,588K
Canceled cashflow
$94,256K
Prepaid expenses and
other current assets
$15,950K
Amortization of premium and
accretion of discounts on...
$8,488K
Accounts receivable, net
$6,744K
Operating lease
right-of-use and other...
$6,363K
Inventory
$413K
Purchases of property and
equipment
$6,638K
Total operating
expenses
$371,113K
Interest expense
$1,512K
Income tax expense
$297K
Back
Back
Cash Flow
source: myfinsight.com
Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. (KURA)